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Abstract
Background: The purpose of this study was to conduct a 20-week controlled trial of lovastatin (10 to 40 mg/day) in
youth with fragile X syndrome (FXS) ages 10 to 17 years, combined with an open-label treatment of a parent-
implemented language intervention (PILI), delivered via distance video teleconferencing to both treatment groups,
lovastatin and placebo.
Method: A randomized, double-blind trial was conducted at one site in the Sacramento, California, metropolitan
area. Fourteen participants were assigned to the lovastatin group; two participants terminated early from the study.
Sixteen participants were assigned to the placebo group. Lovastatin or placebo was administered orally in a capsule
form, starting at 10 mg and increasing weekly or as tolerated by 10 mg increments, up to a maximum dose of 40
mg daily. A PILI was delivered to both groups for 12 weeks, with 4 activities per week, through video
teleconferencing by an American Speech-Language Association-certified Speech-Language Pathologist, in
collaboration with a Board-Certified Behavior Analyst. Parents were taught to use a set of language facilitation
strategies while interacting with their children during a shared storytelling activity. The main outcome measures
included absolute change from baseline to final visit in the means for youth total number of story-related
utterances, youth number of different word roots, and parent total number of story-related utterances.
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Results: Significant increases in all primary outcome measures were observed in both treatment groups. Significant
improvements were also observed in parent reports of the severity of spoken language and social impairments in
both treatment groups. In all cases, the amount of change observed did not differ across the two treatment
groups. Although gains in parental use of the PILI-targeted intervention strategies were observed in both treatment
groups, parental use of the PILI strategies was correlated with youth gains in the placebo group and not in the
lovastatin group.
Conclusion: Participants in both groups demonstrated significant changes in the primary outcome measures. The
magnitude of change observed across the two groups was comparable, providing additional support for the
efficacy of the use of PILI in youth with FXS.
Trial registration: US National Institutes of Health (ClinicalTrials.gov), NCT02642653. Registered 12/30/2015.
Keywords: Fragile X syndrome, Lovastatin, Distance teleconferencing, Expressive language sampling, Narrative
storytelling, Parent-implemented language intervention, PILI
Background
Fragile X syndrome (FXS) is the most common inherited
cause of intellectual disability and the most common
single-gene cause of autism spectrum disorder (ASD) [1, 2].
FXS typically results from a trinucleotide repeat (CGG) ex-
pansion mutation, with a consequent transcriptional silen-
cing of the FMR1 gene and reduction of the encoded
protein, fragile X mental retardation protein (FMRP) [3, 4].
FMRP acts as a translational repressor for a number of
mRNAs that are important for synaptic functioning and
experience-dependent learning [5, 6]. Importantly, the
downstream impact of these changes, such as the elevation
of basal protein synthesis of an extracellular signal kinase
(ERK1/2) signaling pathway, has also been related to the
regulation of learning and social behaviors [7–10].
Clinical trials in FXS have been largely unsuccessful
despite strong preclinical data suggesting phenotypic im-
provement even in adult models [11, 12]. Although there
have been numerous hypotheses regarding the failure of
these trials, there has been a consensus that improved
brain function resulting from a medication may not be
sufficient for improved learning and behavior in the ab-
sence of a parallel systematic enhancement of the learn-
ing environment. In the present study, we conducted a
controlled trial of lovastatin in youth with FXS ages 10
through 17 years, combined with an open-label treat-
ment of a parent-implemented language intervention
(PILI), which has been shown to be independently effica-
cious when delivered to children and adolescents with
FXS [13, 14]. Lovastatin is a specific inhibitor of the
rate-limiting enzyme in cholesterol biosynthesis, 3-
hydroxy-3-methylglutaryl coenzymeA [3HMG-CoA] re-
ductase, and a widely used FDA-approved treatment of
hyperlipidemia in children and adolescents [15]. Rele-
vant to the treatment of FXS, lovastatin also reduces the
activation of the small guanosine triphosphatase
(GTPase) Ras. Consequently, activation of a signaling
molecule downstream to the activation of mGluRs,
specifically ERK1/2, is reduced [16]. Lovastatin has thus
been considered a promising compound in the treatment
of the pathophysiology of FXS.
Pathophysiology of fragile X syndrome
The prevalence of FXS is higher in males than in fe-
males, with FXS observed in approximately 1 in every
3600 to 5000 males and in 1 in every 4000 to 6000 fe-
males [17–19]. Moreover, due to the moderating effects
of the active X chromosome in females [20], males with
FXS are typically more severely affected than are females
with FXS. The phenotypic characteristics of FXS include
hyperactivity, impulsivity, anxiety, and ASD symptom-
atology [21–25]. A number of researchers have argued
that elucidating treatment options for the pathophysi-
ology of FXS may provide insight into the treatment of
etiologically more complex neurodevelopmental disor-
ders, such as ASD or intellectual disability [26–28].
Remarkable advances have been made in understand-
ing the neurobiology of FXS, and as a result, there have
been dozens of investigations using pharmaceutical ther-
apeutics to try to correct the pathophysiology of FXS. In
particular, FMRP has been found to be critical for the
regulation of biochemical processes involved in synaptic
maturation and experience-dependent learning and is
known to be expressed in mature astrocytes and in the
dendrites, spines, and soma of neurons [3]. Moreover,
variability in FMRP expression has been found to be as-
sociated with within-syndrome variability in cognitive
performance [29].
Research findings from knockout (KO) mouse studies
conducted by Bear and colleagues have led to the
mGluR theory of FXS [30–32]. This theory posits that
upregulation of the mGluR5 pathway contributes to
multiple features of the FXS phenotype at the behavioral,
electrophysiological, and molecular levels. Due to the re-
duction or absence of FMRP, enhanced basal protein
synthesis, particularly in the hippocampus, is observed
Thurman et al. Journal of Neurodevelopmental Disorders           (2020) 12:12 Page 2 of 17
[32–34]. Numerous studies have considered the role of
both mGluRs and the signaling pathways downstream of
mGluR receptors as targets for treatment. Reports of
treatment of the FMR1 KO mouse with mGluR5 antago-
nists, as well as genetic studies in which the mGluR5-
deficient mouse is crossed with the KO mouse to rescue
FXS, have provided corroboration for the theory [6, 33].
Moreover, such findings suggest the possibility of rescue
of the FXS phenotype at multiple levels of description,
from molecular to behavioral [6, 32, 33, 35, 36].
Findings from preclinical research considering the use
of lovastatin in the treatment of the phenotypic effects
of FXS have been positive. In the FMR1 KO mouse, lov-
astatin was observed to successfully inhibit Ras and de-
crease the excessive protein production [37]. The
efficacy of lovastatin was assessed in a Canadian phase 1
open-label trial involving 15 individuals with FXS ages 6
to 31 years [38]. Results showed minimal side effects, in-
dicating that lovastatin was well tolerated. Furthermore,
significant improvements were observed in parent rat-
ings of child behavior, clinical improvement ratings
based on caregiver feedback, and parent reporting of
adaptive functioning skills. Finally, there was a reduction
in ERK activity measured in the blood that was corre-
lated with behavioral improvements reported by the
caregivers [38]. Although promising, the findings of this
open-label trial must be replicated in a controlled trial
to more conclusively evaluate efficacy. In the present
study, we conducted a randomized controlled trial but
limited our focus to individuals with FXS between the
ages of 10 and 17 years, matching the age range of long-
term use approved by the United States Food and Drug
Administration [39]. Importantly, there is evidence from
longitudinal studies of the potential for continued
growth in language and cognitive skills in this age range,
even for males with FXS and intellectual disability [40,
41], which suggest a need for treatment options that
capitalize on that potential.
Clinical trials in fragile X syndrome
Unfortunately, the translation of preclinical successes
into human models has proved to be a challenge due to
multiple limitations, such as the outcome measures used
and the study design [42]. One particular challenge in
the translation of preclinical findings into human trials
involves the focus on behavioral changes as a key out-
come. Indeed, Berry-Kravis et al. [42] hypothesized that
even if a pharmaceutical agent is successful in treating
underlying neural mechanisms in FXS, associated behav-
ioral changes may be pleiotropic and/or lag neural
changes. In support of this hypothesis, the use of
pharmaceutical agents in the treatment of other neuro-
psychiatric conditions, such as ADHD, often find that
using medication alone is not adequate to ameliorate
these conditions [43]. In fact, findings from the Multi-
modal Treatment Study of Children with ADHD, a 14-
month, randomized clinical trial in which behavioral and
medication treatment approaches were considered alone
and in combination and contrasted with community/
treatment-as-usual, found that combining medication
and behavioral treatment was most effective in treating
functional skills such as academic achievement and so-
cial skills [40]. In a similar vein, the Child/Adolescent
Anxiety Multimodal Study (CAMS [44, 45];), which is
the largest randomized controlled trial for childhood
anxiety disorders, found that the combination of an SSRI
(sertraline) with cognitive behavioral therapy (CBT) led
to better outcomes than either treatment alone [46]. In
this combined study design, it is believed that the medi-
cation facilitates improved brain functioning that is most
clearly demonstrated in parallel with a behavioral inter-
vention that allows for a systematic enhancement of the
learning environment [47].
In the present study, we combined our controlled trial
of lovastatin with an open-label treatment of PILI, hy-
pothesizing that if lovastatin is effective in treating the
neural mechanisms underlying the FXS phenotype, the
benefits of lovastatin and PILI should be greater than
the benefits of PILI alone. Previous research has demon-
strated the effectiveness of PILI for individuals with FXS
[13, 14]. PILI aims to enhance parent use of a verbally
responsive style of interaction. In this interaction style,
parents [1] talk about and follow the child’s focus of at-
tention, [2] respond to the child’s communicative over-
tures in affectively positive and contingent ways, [3]
solicit the child’s participation in the interaction, and [4]
provide examples of language that are slightly more ad-
vanced than the child’s current communicative level.
There have been numerous demonstrations of the role a
verbally responsive style of parental interaction can play
in supporting the language development of children with
FXS [48].
The presence of attentional difficulties, repetitive be-
haviors and/or interests, and challenging behaviors, such
as frequent attempts to escape demand or social avoid-
ance, in individuals with FXS likely makes it difficult for
parents to be verbally responsive; this, in turn, can nega-
tively impact children’s learning opportunities [49].
Parent-implemented intervention approaches have been
used to successfully target parent verbal responsiveness
by explicitly teaching parents how to respond to their
child and navigate any challenging behaviors and charac-
teristics [50–52]. Moreover, by teaching parents to use
specific strategies for increasing their verbal responsivity,
parents have the potential to use these strategies in their
interactions with their children throughout the day ra-
ther than only when working with the clinicians. The
benefits of parent-implemented interventions have been
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documented for several conditions, including autism
spectrum disorder [51–53] and FXS [54, 55]. Although
most of these interventions focused on young children
and were delivered in the context of object play-based
activities, there is evidence that older children and ado-
lescents, including those with FXS, can also benefit from
this treatment approach. In particular, McDuffie et al.
[13, 14] used distance video teleconferencing (VTC) to
deliver a PILI into family homes to support the language
skills of males with FXS ranging in age from 10 to 17
years. Rather than deliver the intervention within the
context of play, McDuffie et al. embedded the interven-
tion within a shared storytelling context, which was hy-
pothesized to be cognitively accessible and more age-
appropriate and engaging than object play for individuals
in the age range studied. These investigators also pro-
vided antecedent behavior supports to enhance language
development and decrease the likelihood that challen-
ging behaviors would occur during the shared storytell-
ing activities.
Using both a single-case design [14] and a small-scale
randomized controlled trial approach [13], it was found
that mothers receiving PILI learned the targeted inter-
vention strategies, although there was variability in the
rate of acquisition and extent of the use of the respon-
sive strategies among the treated mothers [13]. More-
over, when the parent received PILI, youth with FXS
spent more time engaged in the storytelling activity and
also produced more story-related utterances during the
interactions [13]. Most importantly, the youth with FXS
demonstrated the use of a more diverse vocabulary when
the parent participated in PILI. This treatment gain in
vocabulary use was also observed to generalize to a nar-
rative language sampling context with the parent in the
clinic using a storybook novel to the dyad [13]. These
findings are important because [1] of the relative dearth
of evidence-based nonpharmacological treatment op-
tions available for older children and adolescents with
FXS, and [2] they demonstrated the continued ability of
individuals with FXS to acquire new language skills well
into their adolescent years.
The present study
In the present study, a small-scale controlled trial of lov-
astatin was conducted in 28 youth with FXS ranging in
age from 10 to 17 years. This controlled trial was com-
bined with an open-label treatment of PILI delivered
using distance VTC [13, 14]. The aims were to examine
[1] the efficacy of lovastatin combined with PILI in im-
proving child language outcomes relative to PILI alone,
with a greater positive change in child language expected
in the combined condition [2]; the relationship of parent
use of the targeted responsive strategies to child lan-
guage outcomes, with greater strategy use expected to
be associated with greater change in child language; and
[3] potential biomarkers of lovastatin-induced change,
focusing on the cellular/molecular mechanisms by which
lovastatin influences MEK/ERK and Rho GTPase signal-
ing pathways.
Methods
Participants
Thirty participants (28 males and 2 females) with FXS
ages 10 through 17 years were enrolled in this study. All
participants had a DNA-confirmed FMR1 full mutation.
Additional inclusion criteria were [1] willingness of both
the youth participant and parent/caretaker to participate
in the protocol [2]; use of speech as the primary mode
of communication for the youth participant, with multi-
word utterances used at least occasionally [3]; youth IQ
of less than or equal to 70 at screening; and [4] use of a
medically acceptable method of birth control and nega-
tive serum or urine pregnancy test at screening, for
sexually active female participants of childbearing
potential.
Participants were excluded from the trial if any of the
following criteria were met by the youth: [1] not primar-
ily English speakers [2]; medication changes in the 4
weeks before screening [3]; major behavioral therapy or
educational programming changes during the study,
other than scheduled school holidays [4]; disease or con-
dition (medical or surgical) at the screening that might
compromise participant health or interfere with absorp-
tion, distribution, metabolism, or excretion of lovastatin
[5]; any other reason that, in the opinion of the lead
physician, rendered a youth with FXS unsuitable to par-
ticipate in this study, including being unable to comply
with the requirements of the study or displaying clinic-
ally significant abnormalities on safety assessments con-
ducting during screening, use of prohibited medications
per lovastatin package insert, history of recurrent status
epilepticus, inability to withhold grapefruit and grape-
fruit juice from diet during the entire clinical trial (a fac-
tor associated with increased risk of side effects of
lovastatin), unwillingness to abstain from alcoholic bev-
erages during the trial, and active suicidality.
Design
Primarily, participants were recruited from the Sacra-
mento, California, metropolitan area, with an extension
of recruitment nationwide to families capable of travel-
ing to and from the clinic to complete all necessary as-
sessments. Participants were screened initially using a
pre-screening form either over the phone or in person at
the clinic. Potentially eligible participants were then
scheduled for a screening visit to complete assessments
to confirm whether language level, current health, and
overall functioning were appropriate for inclusion.
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Eligible youth participants were randomized to drug or
placebo in a double-blind design with all families partici-
pating in the PILI. UC Davis Investigational Drug Ser-
vices carried out randomization to lovastatin or placebo
via a computer algorithm (see Fig. 1). This process re-
sulted in 14 participants assigned to the lovastatin group
and 16 participants assigned to the placebo group (see
Table 1). The study drug was administered orally in cap-
sule form, starting at 10mg of lovastatin or placebo once
daily in the evening and increasing by 10mg increments
on a weekly basis or as tolerated through the first 4 weeks
of the study, up to a maximum dose of 40mg daily. Dose
tolerance was assessed weekly during this titration period
by phone call or email correspondence between the parent
and study physician, with a single-dose decrease allowed
per protocol during this period. Each participant stabilized
at a maximum tolerated dose when he/she completed the
4-week titration period or after a dose decrease, whichever
came first. The maximum tolerated dose was then main-
tained for the duration of the study. Parents were con-
tacted approximately every other week by study staff to
assess for possible adverse events and to verify proper dos-
ing. A 10-week supply of study drug was dispensed at
baseline and again at the week 10 visit. Any remaining
study drug was collected at each subsequent visit to meas-
ure compliance. Compliance was also monitored using a
daily dosing diary maintained by the caregiver and
reviewed at each visit.
Fig. 1 Consolidated standards of reporting trials (CONSORT) flow diagram of subject disposition
Table 1 Descriptive statistics of patient characteristics at pre-
treatment clinic visit
Measure Lovastatin Placebo P value
N, enrolled 14 16
N, incomplete 2 0
Age 13.86 ± 2.14 13.17 ± 2.54 0.4307
Sex 0.2092
Male 12 16
Female 2 0
Race/ethnicity 0.05
Caucasian 14 10
Hispanic 0 4
African American 0 1
Asian 0 1
Leiter-R Brief IQ standard score 44.00 ± 9.22 43.13 ± 6.24 0.7604
Leiter-R growth score 461.40 ± 13.32 462.30 ± 8.57 0.8273
ADOS-2 comparison score 6.85 ± 2.54 6.75 ± 2.05 0.911
Parent education level 0.764
HS grad/GED 0 1
BA/BS 5 6
Master’s degree + 4 4
Some college 2 5
Some grad work 1 0
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Parent-implemented language intervention
The PILI was delivered entirely in the participants’
homes through study-provided laptops (i.e., MacBook
Air TM laptop) with pre-installed VTC (i.e., Skype) and a
built-in webcam over the 20-week treatment period.
These sessions were conducted by an ASHA-certified
Speech-Language Pathologist (SLP) in collaboration with
a Board-Certified Behavior Analyst (BCBA). A full de-
scription of the intervention can be found in McDuffie
et al. [13, 14].
In the intervention, the value of verbal responsiveness
and story-related talking (i.e., providing rich story-
related models of vocabulary and grammar) were ex-
plained to the parent. Moreover, parents were taught
how to use recasts, WH questions, and fill-in-the-blank
(FIB) prompts to support their child’s active participa-
tion in the interaction (see Table 2 for the description of
the strategies). The language intervention began with 2
parent education sessions delivered by an SLP that pro-
vided a rationale for the targeted strategies, as well as
video examples of strategy use. The intervention then
continued for approximately 12 weeks with 4 activities
per week (see Table 3 for the description of activities); a
break occurred during the midpoint of the treatment to
allow for the week 10 onsite visit to be completed. The
teaching of the parents was embedded in the context of
shared storytelling using wordless picture books that the
study team digitized and uploaded to an iPad AirTM
using the Apple iBooksTM application. The picture
books served as a shared conversational topic for the
weekly intervention activities. The parents also received
example scripts to serve as a guide when completing the
shared storytelling.
Prior to starting the language intervention, families
completed 3 shared storytelling interactions in the home
via VTC. Following these interactions, each participating
parent met with a BCBA via VTC to discuss challenging
behaviors that could occur during the shared storytell-
ing. Based on this interview, each family received one
behavior strategy education session during which the
BCBA reviewed an individualized behavior management
plan with the parent (e.g., use of reinforcement strat-
egies, suggestions for managing challenging behaviors).
This education session was followed by 3 behavior strat-
egy practice sessions. During these practice sessions,
parent-child dyads revisited the picture books used dur-
ing their pre-treatment shared storytelling interactions
while the BCBA provided real-time feedback via VTC
regarding behavior management strategies that the par-
ent could implement.
Study measures
Safety assessments
Physical and neurological examinations, along with vital
sign measurements, were completed at each visit for
safety monitoring. Adverse events were documented at
each visit. Standard laboratory tests of the blood and
urine, including the complete blood count with differen-
tial and platelets, comprehensive metabolic panel, and
lipid panel, were also performed at each visit. At base-
line, molecular testing, using plasma, to confirm FXS
diagnosis was carried out by PCR approach as described
in Tassone et al. [56].
Efficacy assessment metrics
Participating caregivers completed 3 language samples
with their child during both the pre- and post-treatment
period. Samples were collected during a shared storytell-
ing activity. Samples were collected over a period of ap-
proximately 8 days on average (SD = 2.73, range 4–15
days) for the lovastatin+PILI group and 7 days for the
placebo+PILI group (SD = 1.51, range 2–9 days) follow-
ing the pre-treatment clinic visit and over a period of ap-
proximately 4.25 days (SD = 2.45, range 2 to 9 days) for
the lovastatin+PILI group and 3.9 days (SD = 3.24, range
2–14 days) for the placebo+PILI group prior to the post-
treatment clinic visit. Timespan in days did not differ
significantly between the 2 groups at both time points
(pre: p = 0.2261; post: p = 0.7406). Three pairs of books
were used for the language samples in the home (Set A:
Harry and the Lady Next Door by Gene Zion, Flap Your
Wings by P.D. Eastman and Strike Three, Marley! by
Table 2 Description of the specific PILI verbal response strategies
Recasts Models of a more mature version of the youth’s verbalization that provided an opportunity to learn new linguistic means
of expressing the same meaning (e.g., “boy run” could be recast as “the boy is running in the yard.”). Recasts also serve to
acknowledge and reinforce the youth’s conversational turn.
WH questions Open-ended WH questions (e.g., “What is the boy doing?” and “How is the boy feeling?”) that prompt the child to provide
an on-topic verbal response, engage the youth with FXS in the storytelling activity, support his/her practice of language
skills, and improve the youth’s understanding of story details as well as his/her ability to retell the story in his/her own
words. The youth’s responses provide an opportunity for the parent to recast the youth’s verbalization or provide story-
related talking to model the appropriate response.
Fill-in-the-blank (FIB)
prompts
Starting a sentence and then using a rising intonation and pause to mark an expectation that the youth with FXS is to
complete the sentence (e.g., “the doggy is being chased by the …” that prompts the youth to say, “girl”). FIBs convey to
the youth that an on-topic response is expected and support successful participation in the storytelling, but with minimal
linguistic demands on the youth with FXS. The youth’s responses to a FIB prompt provided an opportunity for the parent
to recast the youth’s verbalization or provide story-related talking to model the appropriate response.
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John Grogan; Set B: Harry by the Sea by Gene Zion, The
Best Nest by P.D. Eastman, and Marley’s Big Adventure
by John Grogan). Book selection was counterbalanced
across participants. Unlike the shared storytelling activ-
ities utilized during the intervention, the parent was not
provided with scripts or clinician feedback for these
samples. None of these books were used in the interven-
tion sessions.
All samples of talk in the pre- and post-treatment
storytelling interactions were recorded and transcribed
by experienced transcribers using the Systematic Ana-
lysis of Language Transcripts, 2012 (SALT [57];), a soft-
ware program that performs standard and customized
analyses of text files that have been prepared according
to a standard set of conventions that are commonly uti-
lized in child language research (e.g., segmenting a word
into root and plural morphemes: “dog/s”). The following
process was used to transcribe the study samples: [1]
each sample was transcribed first by a “primary” tran-
scriber, [2] a “secondary” transcriber compared the
resulting transcript against the recording and noted any
perceived discrepancies, and [3] the “primary” tran-
scriber then finalized the transcript after reviewing any
discrepancies and updating the transcript as he/she
deemed appropriate. Transcribers were blinded to infor-
mation about the participant and when the sample was
recorded (e.g., whether pre- or post-treatment).
The finalized SALT transcripts were then coded for
parent story-related utterances, which included the par-
ent’s use of the specific targeted intervention strategies
(i.e., recasts, open-ended WH questions, and FIB
prompts), utilizing the procedures outlined by McDuffie
et al. [13]. The following outcome efficacy metrics were
derived from these samples: child total number of story-
related utterances, child number of different word roots
(NDWR), and parent total number of story-related utter-
ances. In addition, parental use of the specific targeted
intervention strategies was considered in secondary ana-
lyses (see Table 4 for additional information on each of
these metrics.) Interobserver agreement was conducted
on 18 samples by computing intraclass correlations for
the specific targeted intervention strategies, parent story-
related utterances, and youth story-related utterances.
Intraclass correlation coefficients were above 0.95 for all
metrics.
Autism Diagnostic Observation Schedule, Second Edition
The Autism Diagnostic Observation Schedule-2 (ADOS-
2) [58] is a semi-structured observational context de-
signed to observe reciprocal interaction skills in addition
to the presence of repetitive behaviors. One of four
ADOS-2 modules is administered based upon the partic-
ipant’s expressive language level. In the current project,
this measure was completed at the pre-treatment clinic
visit, and the ADOS-2 comparison score was used to de-
scribe the participant characteristics of the 2 treatment
groups.
Nonverbal cognition
The Leiter International Performance Scales - Revised
(Leiter-R [59];) is a standardized assessment of nonver-
bal cognition, which is administered nonverbally through
the use of pantomime and gestures. The subtests com-
prising the Brief IQ were administered. The mean IQ in
the standardization sample was 100 (SD = 15). In the
current project, this measure was completed at the pre-
Table 3 Description of the PILI sessions conducted each week
Coaching session The clinician delivered a real-time coaching session to the parent as he/she interacted with the youth with FXS in shared story-
telling. The coaching was provided to the parent via a single earbud headphone so that the child could not hear the clinician.
Homework session The parent independently video-recorded a homework session in which he/she engaged in a shared storytelling activity with
the youth with FXS using the same book as in coaching. The video was uploaded to the clinician via a secure cloud-based
platform.
Feedback session The clinician provided feedback to the parent regarding the homework in a VTC session.
Final storytelling
session
The clinician observed, without coaching or intervention, a final storytelling session between parent and youth with FXS. This
session was video recorded for subsequent analysis of parental strategy use and youth language and communication. A
different book was used by the parent each week so that he/she gained practice in the responsive strategies and the dyad
practiced the shared storytelling process rather than simply memorizing how to tell a particular story.
Table 4 Efficacy assessment composite metrics computed from the three pre- and post-treatment language samples collected by
the parent
Youth total number of story-related
utterances
The total number of child utterances directly related to the semantic or conceptual content of the story.
Repetitions and completely unintelligible utterances were not included. This metric provides an index of the
total amount of child talk.
Youth number of different word
roots (NDWR)
The NDWR in the first 50 story-related utterances or in the child’s total number of story-related utterances if the
child produced less than 50 story-related utterances. This metric provides an index of child vocabulary size.
Parent total number of story-
related utterances
The total number of story-related parent utterances. This metric includes parent’s use of the specific strategies
taught in the intervention (i.e., recasts, WH-questions, and fill-in-the-blank prompts) and provides an index of
the total amount of parent talk.
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treatment clinic visit and the Brief IQ standard score
was used to describe the participant characteristics of
the 2 treatment groups.
Language
Multiple individually administered standardized tests
were included. Receptive vocabulary was assessed using
the growth scores from the Peabody Picture Vocabulary
Test, 4th Edition (PPVT-4) [60]. Expressive vocabulary
was assessed using growth scores from the Expressive
Vocabulary Test, 2nd Edition (EVT-2) [61], which was
co-normed with the PPVT-4. Receptive grammar was
assessed using the total number of blocks passed on the
Test for Reception of Grammar [62]. Finally, expressive
grammar was assessed using raw scores from the Syntax
Construction subtest of the Comprehensive Assessment of
Spoken Language [63]. All assessments were completed
in the clinic at both the pre- and post-treatment clinic
visits.
Behavioral rating scales
Performance on 2 behavioral rating scales was consid-
ered within analyses. First, the total score from the Re-
petitive Behavioral Scale-Revised (RBS-R [64];), an
informant questionnaire designed to assess the presence
of restricted and repetitive behaviors, was considered in
analyses. In this measure, 43 items are rated using a 4-
point Likert scale, with higher scores indicative of in-
creased severity of repetitive behaviors. Second, the total
score from the Aberrant Behavior Checklist-Community
(ABC-C [65];), an informant questionnaire designed to
be used to assess the presence of maladaptive behaviors,
was considered. In this measure, 58 items are rated using
a 4-point Likert scale ranging from 0 (not a problem) to
3 (the problem is severe in degree). These behavior rat-
ing scales were completed at the pre- and post-
treatment clinic visits.
Clinical rating scales
Three clinical rating scales were used to assess the study
clinician’s impression of youth improvements over the
course of the treatment period. First, performance on
the Clinical Global Impressions Scale (CGI) [66] was
assessed by the study clinician at the pre-treatment
clinic visit, using a Likert-scale ranging from 1 (normal)
to 7 (extreme) to rate symptom severity. The level of
CGI improvement was assessed by the clinician at the
study midpoint as well as at the post-treatment clinic
visit, using a Likert scale ranging from 1 (very much im-
proved) to 7 (very much worse). In addition, a visual
analog scale (VAS) was used to assess parental impres-
sions of progress in two key symptoms: spoken language
impairment and social impairment. Using this approach,
the distance (cm) of the parent’s mark from one end of a
10-cm scale is used as the outcome variable for analysis
[67–69]. Clinicians and parents were blind to whether
the youth with FXS was receiving lovastatin or placebo.
Biomarkers’ plasma activity levels
Plasma samples were collected using EDTA-containing
blood collection tubes. The blood was centrifuged for
10 min at 1000×g within 2 h of blood collection. The
plasma was removed, aliquoted, and stored at − 20 °C.
Samples were 1:20 diluted in assay buffer before testing.
Plasma ERK, S6K, and MMP-9 activities were measured
using the Phospho/Total ERK and Phospho/Total S6K1
2-Plex Magnetic Bead Kit and the Human MMP-
Magnetic Bead Panel 2 (Merck Millipore, Billerica, MA).
The preparation of plasma samples and reagents was
performed according to the manufacturer’s protocol.
Briefly, plates were washed with wash buffer before load-
ing controls and samples to the appropriate wells. For
MMP-9, magnetic beads, added to each well, were incu-
bated for 2 h at room temperature followed by a washing
step. Detection antibodies added to the plate were incu-
bated for 1 h at room temperature. Streptavidin-
phycoerythrin was incubated for 30 min at room
temperature, and plates were washed twice with wash
buffer. Sheath fluid was added to each well, and the
plates were run on Luminex® (50 μL, 50 beads per bead
set). For ERK and S6K1 activity levels, the plates were
incubated overnight at 40 °C with shaking in the dark,
following by washing, detection antibody, and incubation
at room temperature for 1 h in the dark. Detection anti-
bodies were removed and streptavidin-PE (SAPE) was
added followed by a 15-min incubation at RT with shak-
ing in the dark. The amplification buffer was added on
top of the reaction mixture and the SAPE and amplifica-
tion buffer were removed, and the beads were resus-
pended in assay buffer. Quality controls, negative and
positive controls, and target samples were run in dupli-
cates. The plates were run on Luminex® with xPONENT
software. The median fluorescent intensity (MFI) data
was analyzed using the spline curve-fitting method for
calculating the concentrations of the markers in each
sample.
Analysis plan
Data analyses were performed with SAS software, ver-
sion 9.4 [70]. Results were expressed as mean ± standard
deviation (SD) or frequencies (%). Data for each variable
were examined for normality using the Shapiro-Wilk test
and Kolmogorovo-Smirnov test. Not normally distrib-
uted variables were logarithmically transformed to
achieve normality prior to statistical analyses. The ana-
lysis of treatment efficacy was carried out using the ana-
lysis of covariance (ANCOVA), adjusted for the
corresponding baseline score as a covariate. Fisher’s
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exact test was applied to categorical variables. Correla-
tions between two variables were assessed with Pearson’s
correlation, and group comparisons were carried out
using Fisher’s Z test. Student’s paired t tests were used
to compare means before and after intervention for the
same subjects within each treatment group. Adverse
events were summarized by severity and relation to the
drug. Two-tailed P values less than 0.05 were considered
statistically significant as appropriate.
Results
Adverse events and safety assessments
Two participants (out of 30), assigned to the lovastatin+-
PILI group, terminated early from the study following
adverse events; in both of these instances, a moderate in-
crease in irritability was reported. No between-group dif-
ferences were observed in terms of the [1] total number
of participants experiencing the different types of ad-
verse events or [2] the total number of adverse events as
a function of severity (see Table 5). In addition, no rela-
tionship was established between lovastatin and the oc-
currence of adverse events (see Table 5). No severe
adverse effects were reported during the study.
In addition, as would be expected when using lova-
statin, a significant difference was observed in total chol-
esterol level between the treatment groups (p < .0001),
with a significant decrease in total cholesterol level for
the lovastatin+PILI group (baseline: M = 134.67, SD =
19.27; post: M = 104.75, SD = 17.85, p < .0001) over the
course of the study period, but no significant change
found in the placebo+PILI group (baseline: M = 132.27,
SD = 19.3; post: M = 134.13, SD = 21.54, p = .652). Simi-
larly, a significant between-group difference (p < 0.0001)
was observed in LDL-cholesterol levels between the
lovastatin+PILI group (baseline: M = 73.75, SD = 15.66;
post: M = 47.33, SD = 14.69, p < .0001) and the place-
bo+PILI group (baseline: M = 70.47, SD = 15.35; post:
M = 73.87, SD = 16.45, p = 0.368), in which participants
in the lovastatin+PILI group, but not the placebo+PILI
group, demonstrated a significant decrease in LDL-
cholesterol levels. Finally, a between-group difference (p
= .03) was observed in alanine aminotransferase between
the lovastatin+PILI group (baseline: M = 22.08, SD =
10.02; post: M = 24.67, SD = 9.33) and the placebo+PILI
group (baseline: M = 19.93, SD = 11.13; post: M = 18.13,
SD = 7.75); however, significant changes were not ob-
served during the study when groups were considered
individually (lovastatin+PILI: p = 0.062; placebo+PILI: p
= 0.432). In all cases, the means observed were all within
the normal range.
Treatment efficacy analyses
Primary outcome measures
Means and standard deviations at both pre- and post-
treatment for the primary outcome measures reported in
this study are presented in Fig. 2 as a function of the
treatment group. A significant improvement in child
total number of story-related utterances, after adjusting
for pre-treatment values, was observed for both the
lovastatin+PILI group (t (11) = 6.94, p < 0.001) and the
placebo+PILI group (t (11) = 3.92, p = 0.0014). No
between-group difference was observed in the amount of
change that occurred across the treatment period (F (1,
25) = 0.95, p = 0.3379). Similarly, a significant improve-
ment in the NDWR produced by the youth, after adjust-
ing for pre-treatment values, was also observed both for
the lovastatin+PILI group (t (11) = 6.14, p < 0.001) and
for the placebo+PILI group (t (11) = 4.62, p = 0.0003).
Again, after adjusting for pre-treatment performance,
the amount of change experienced did not differ
Table 5 Characterization of adverse events experienced by youth with FXS
Total number of participants1
Treatment group No AE Mild event Moderate event Serious event Between-group comparison
Lovastatin 1 10 1 0 0.3734
Placebo 3 9 4 0
Total number of adverse events2
Treatment Group Mild event Moderate event Serious event Between-group comparison
Lovastatin 31 1 0 0.2488
Placebo 38 7 0
Total number of adverse events: relationship3
Treatment group Not related Unlikely Probably related Between-group comparison
Lovastatin 10 12 10 0.8172
Placebo 14 21 20
1Number of participants experiencing a certain severity of an adverse event where each participant is counted only once at the highest level of severity for
the event
2Total number of adverse events experiencing a certain severity of an adverse event, including recurrence of same adverse event
3Total number of adverse events determined to be related to study drug (lovastatin), including recurrence of same adverse event
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significantly between the two groups (F (1, 25) = 2.05, p =
0.1644). Finally, a significant improvement in parent
total number of story-related utterances used was also
observed both for the lovastatin+PILI group (t (11) =
10.31, p < 0.001) and for the placebo+PILI group (t (11)
= 6.94, p < 0.001). Again, the amount of change in par-
ent total number of story-related utterances did not dif-
fer across the two groups (F (1, 25) = 2.69, p = 0.1135)
after adjusting for pre-treatment performance.
Secondary outcome measures
Means and standard deviations at both baseline and
post-treatment for the secondary outcome measures re-
ported in this study are presented in Table 6 as a
function of the treatment group. Gains were observed in
each of the 3 specific strategies taught to parents (i.e., re-
casts, WH questions, FIB prompts) for both the lovasta-
tin+PILI group (recasts: t (11) = − 8.01, p < 0.0001; WH
questions: t (11) = − 6.90, p < 0.0001; FIB prompts: t
(11) = − 5.34, p = 0.0002) and the placebo+PILI group
(recasts: t (15) = − 6.46, p < 0.0001; WH questions: t
(15) = − 4.69, p = 0.0003; FIB prompts: t (15) = − 4.01,
p = 0.0011). No between-group differences were ob-
served in the amount of change that occurred over
the course of the treatment period, after adjusting for
baseline performance, in any of the strategies taught (re-
casts: F (1, 25) = 2.72, p = 0.1117; WH questions: F (1, 25) =
2.88, p = 0.1021; FIB prompts: F (1, 25) = 0.68, p = 0.4158).
Fig. 2 Means (with standard deviation error bars) for the primary outcome measures as a function of the treatment group. Note that all
comparisons are significant (p < .05) after controlling for pre-treatment values
Table 6 Group comparison (mean ± SD) in secondary outcome measures between patients on lovastatin vs. placebo
Outcome Lovastatin+PILI Placebo+PILI
Baseline Post Baseline Post
Receptive vocab growth score 134.75 ± 31.76 136.92 ± 33.87 137.44 ± 22.71 136.44 ± 19.79
Expressive vocab growth score 143.5 ± 22.12 142.67 ± 24.53 141.44 ± 14.45 142.75 ± 12.91
Expressive grammar raw score 10.18 ± 11.36 11 ± 12.66 8.33 ± 6.41 9.93 ± 7.59
Receptive grammar raw score 22.18 ± 18.91 22.17 ± 20.23 21.4 ± 9.26 20.2 ± 11.98
Parent strategy: recasts 3.28 ± 2.67 29.67 ± 13.34 5.48 ± 5.07 24.79 ± 12.57
Parent strategy: WH-questions 9.56 ± 9.06 40.36 ± 20.69 13.19 ± 8.57 33.25 ± 17.73
Parent strategy: fill-in-the-blank prompts 2.06 ± 2.74 19.56 ± 11.96 3.21 ± 6.96 16.5 ± 14.24
ABC-C – total score 44.5 ± 28.43 40.5 ± 31.83 55.5 ± 30.18 44.06 ± 25.36
RBS-R – total score 27.75 ± 17.43 28.67 ± 23.9 32.19 ± 18.84 26.19 ± 20.14
Clinical Global Impression (CGI) 4.581 ± 0.67 2.422 ± 0.67 4.501 ± 0.63 2.382 ± 0.72
VAS: spoken language impairment 4.06 ± 2.43 5.66 ± 1.99 1.94 ± 1.41 4.18 ± 1.53
VAS: social impairment 3.73 ± 1.74 5.18 ± 1.70 2.55 ± 1.36 3.99 ± 2.06
1CGI-severity ratings collected at baseline visit
2CGI-improvement ratings collected at post-treatment visit
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Considering the direct assessments of language admin-
istered during the study period (i.e., receptive vocabu-
lary, expressive vocabulary, receptive grammar, and
expressive grammar), the performance for the lovasta-
tin+PILI group and the placebo+PILI group was com-
parable over the course of the study, with neither group
demonstrating significant language gains over the course
of the project (ps ranging from 0.07–0.78).
No between-group differences were observed in the
CGI-improvement ratings conducted at the post-
treatment visit (F1,25) = 0.03, p = 0.8592), after adjusting
for pre-treatment CGI-severity of these ratings. In
addition, both groups demonstrated significant improve-
ment in parent report of severity of spoken language im-
pairment (lovastatin+PILI group: t (11) = − 5.30, p =
0.003; placebo+PILI group: t (11) = − 8.19, p < 0.0001)
and social impairment (lovastatin+PILI group: t (11) = −
5.80, p = 0.0001; placebo+PILI group: t (11) = − 4.46, p =
0.0005). No between-group differences were observed in
the amount of change that occurred across the groups in
either of these metrics after accounting for baseline
levels of performance (VAS severity of spoken language
impairment: F (1, 25) = 0.08, p = 0.7861; VAS severity of
social impairment: F (1, 25) = 0, p = 0.9781).
Significant improvements were observed in the ABC-C
total scores for the placebo+PILI group, but not the
lovastatin+PILI group (lovastatin+PILI group: t (11) =
0.90, p = 0.3873; placebo+PILI group: t (15) = 2.67, p =
0.0174); however, no between-group differences were
observed in the amount of change across the treatment
period (F (1, 25) = 0.76, p = 0.3931). No significant im-
provements were observed in the RBS-R total scores for
either group (lovastatin+PILI group: t (11) = 0.26, p =
0.7997; placebo+PILI group: t (15) = 1.63, p = 0.1231).
Associations between parent use of treatment strategies
and youth outcomes
Next, the authors considered the associations between
parent total number of story-related utterances and
youth outcomes. Results from these analyses indicate
that percent change in parent total number of story-
related utterances was significantly associated with youth
gains in both total number of story utterances and
NDWR produced for the placebo+PILI group, but not
for the lovastatin+PILI group (see Table 7). Indeed, the
strength of the association between increases in parent
total number of story-related utterances and youth gains
in both of these variables was significantly stronger in
the placebo+PILI group than it was in the lovastatin+-
PILI group (ps < 0.046).
In addition, the associations between the percent
change scores between parent total number of story-
related utterances and the secondary youth outcomes
(i.e., CGI-I, parent report of severity of spoken language
impairment, parent report of severity of social impair-
ment) were considered (see Table 7). Of these analyses,
only the associations between percent change in parent
total number of story-related utterances and post-
treatment CGI-I ratings were observed to differ signifi-
cantly between the 2 treatment groups; however, the
within-group correlations between CGI-I ratings and the
percent of change in parent total number of story-
related utterances observed did not meet criteria for a
significant association in either treatment group.
Biomarkers of lovastatin-induced change
Analyses were conducted to consider lovastatin-induced
change in the set of biomarkers assayed, focusing on the
cellular/molecular mechanisms by which lovastatin in-
fluences MEK/ERK and Rho GTPase signaling pathways.
To begin, no differences were observed between the
lovastatin+PILI and placebo+PILI groups in FMR1 mea-
sures, including the percent of methylation and CGG al-
lele category (see Table 8). Metrics of MMP9, ERK, and
S6K were comparable across the lovastatin+PILI group
and placebo+PILI group over the course of the study,
with neither group demonstrating a significant change in
any of these markers after accounting for pre-treatment
measures (see Table 9).
Discussion
Findings from preclinical research and from a phase 1
open-label trial in individuals with FXS considering the
use of lovastatin in the treatment of the phenotypic ef-
fects of FXS have been positive [37, 38]. The present
study was designed to provide a controlled trial of lova-
statin, combined with an open-label treatment of a PILI
that has been shown to be effective in youth with FXS
Table 7 Correlations of parent sum strategies used with a given youth outcome
Outcome Lovastatin+PILI Placebo+PILI Between-group
comparisonCorr coeff. r Within-group (H0: r = 0) Corr coeff. r Within-group (H0: r = 0)
Child total # of utterances − 0.095 z = − 0.10 (0.7742) 0.647 z = 0.77 (0.0054) z = − 2.0 (0.0455)
Child # different words − 0.194 z = − 0.20 (0.5562) 0.704 z = 0.88 (0.0016) z = − 2.47 (0.0135)
Clinical Global Impression (CGI) - Improvement − 0.38 z = − 0.41 (0.2243) 0.43 z = 0.46 (0.0991) z = − 1.98 (0.0477)
VAS: spoken language impairment 0.306 z = 0.32 (0.3425) 0.299 z = 0.31 (0.2663) z = 0.02 (0.9840)
VAS: social impairment 0.356 z = 0.37 (0.2643) − 0.378 z = − 0.39 (0.1568) z = 1.78 (0.0751)
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[13]. Using this combined study design, the authors hy-
pothesized that, if lovastatin is indeed effective in treat-
ing neural mechanisms underlying the FXS phenotype,
the benefits of combining lovastatin and PILI would be
greater than the benefits of PILI alone; that is, the posi-
tive effects of lovastatin would be most clearly demon-
strated when combined with a behavioral intervention
that allows for a systematic enhancement of the learning
environment. The primary hypothesis was not supported
in that no clear benefit of lovastatin over placebo was
found, although additional evidence of the efficacy for
PILI was obtained.
Adverse events and safety assessments
Lovastatin is an FDA-approved statin that is widely used
in the treatment of hyperlipidemia in children and ado-
lescents [15]. This known safety profile, paired with
promising findings from preclinical research considering
the use of lovastatin in the treatment of the phenotypic
effects of FXS, has encouraged efforts to conduct human
trials to consider the efficacy of lovastatin in FXS. In the
present study, lovastatin produced minimal adverse
events. Moderate increases in irritability were observed
for 2 participants in the lovastatin group, who then ter-
minated early from the study. In both cases, the partici-
pants were observed to have pre-treatment irritability
rating scores in the upper half of the lovastatin group
score range. The total number of participants experien-
cing adverse events and the total number of adverse
events as a function of severity did not differ signifi-
cantly between the lovastatin and the placebo groups. As
would be expected when using lovastatin, decreases in
total cholesterol level and in levels of LDL cholesterol
were observed in the lovastatin group, but not in the
placebo group, with means for clinical labs in the normal
range [38]. In addition, a significant difference was ob-
served in alanine aminotransferase, an enzyme found
primarily in the liver and kidney that is used to screen
for/monitor liver disease, between the 2 treatment
groups. Nevertheless, neither the treatment group dem-
onstrated significant levels of change in alanine amino-
transferase across the treatment period, and participant
means were within the normal range. Although these
data provide support for the short-term safety of statins
in individuals with FXS who present with normal choles-
terol levels, long-term studies are warranted. Moreover,
lipid monitoring, and potentially alanine aminotransfer-
ase monitoring, should be included in any future lova-
statin trial.
Treatment efficacy
We found no significant differences in the magnitude of
change observed across the study period between the
participants receiving lovastatin and those receiving pla-
cebo on the primary or secondary outcome measures.
Thus, we failed to replicate the findings of the open-
label study conducted by Çacu et al. [38]. The different
findings of the two studies may reflect the fact that our
youngest participant was 10 years of age compared to 6
years in the Çacu et al. study. Indeed, it has been sug-
gested that there is a need to test the efficacy of medica-
tion in toddlers and preschoolers with FXS to ensure
maximum brain plasticity as well as to avoid the need to
overcome long years of missed learning opportunities
Table 8 Group comparison for distributions of allele categories and % methylation for mosaic alleles between patients on lovastatin
vs. placebo
Variable Lovastatin+PILI Placebo+PILI Between-group comparison
Allele category, n (%) Fisher’s exact test Prob = 0.0211 (0.1717)
Full mutation 9 (75%) 7 (43.75%)
Methylation mosaic 0 4 (25%)
Size mosaic 3 (25%) 5 (31.25%)
% Methylation for mosaic alleles, mean ± SD 85.67 ± 9.29 75.22 ± 11.98 F (1, 10) = 1.86 (0.2026)
Table 9 Group comparison (mean ± SD) in molecular biomarkers between patients on lovastatin vs. placebo
Biomarker Lovastatin+PILI Placebo+PILI Between-group comparison
Baseline Post Within-group:
baseline vs. post
Baseline Post Within-group:
baseline vs. post
Baseline Post Post, adjusted for
baseline
MMP 6.36 ±
2.84
6.25 ±
2.48
t (11) = − 0.09
(0.9313)
6.69 ±
3.65
7.20 ±
4.10
t (12) = − 0.99
(0.3407)
F (1, 24) = 0.01
(0.9383)
F (1, 23) = 0.18
(0.675)
F (1, 22) = 0.48
(0.4935)
ERK 0.48 ±
0.26
0.58 ±
0.32
t (11) = − 0.62
(0.5502)
0.50 ±
0.22
0.84 ±
0.98
t (12) = − 1.16
(0.2676)
F (1, 23) = 0.16
(0.6911)
F (1, 23) = 0.57
(0.4599)
F (1, 22) = 0.64
(0.4332)
S6K 0.11 ±
0.10
0.11 ±
0.11
t (11) = 1.11 (0.2891) 0.14 ±
0.26
0.08 ±
0.04
t (11) = 0.66 (0.5203) F (1, 23) = 0.08
(0.7772)
F (1, 22) = 0.07
(0.7878)
F (1, 21) = 0.09
(0.772)
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and the development of maladaptive learning strategies
[42]. This explanation seems unlikely however, given
that nearly half of the participants in the Çacu et al.
study were over the age of 18 years. Moreover, there is
evidence from longitudinal studies of the potential for
continued progress in language learning during adoles-
cence of individuals with FXS even in the absence of any
systematic language intervention [40, 71]. It is also pos-
sible that the different outcome measures used in the
two studies are the source of the discrepant results. The
primary outcome measure for Çacu et al. was not fo-
cused on language, but on behavioral problems as
assessed by the Aberrant Behavior Checklist-Community
[65]. However, the ABC-C was a secondary outcome in
the present study and showed no differential improve-
ment between the placebo and lovastatin-treated partici-
pants. Thus, it may be that the gains observed in that
Çacu et al. study were due to factors other than treat-
ment with lovastatin, which cannot be ruled out given
the open-label study design. In any event, the present re-
sults provide no evidence to support the use of lova-
statin as a treatment for learning or behavior problems
in individuals with FXS who are in late childhood or
adolescence.
In contrast to the results for lovastatin, the present
study provided additional evidence for the efficacy of
PILI as a treatment for language problems in youth with
FXS. In particular, we observed significant increases,
over the course of the treatment period, in the total
number of story-related utterances produced by the
child, the total NDWR produced by the child, and the
total number of story-related utterances produced by the
parent in both the lovastatin+PILI group and the place-
bo+PILI group. Moreover, significant gains were ob-
served, in both treatment groups, in each of three
specific strategies taught to parents (recasts, WH ques-
tions, FIB prompts). Finally, significant improvements in
parent reports of the severity of spoken language and so-
cial impairments were observed in both treatment
groups. In all cases, the amount of change observed over
the course of the treatment period did not differ be-
tween the two treatment groups.
Taken together, these data provide additional support
that parents are able to learn the PILI-targeted interven-
tion strategies (i.e., recasts, WH questions, and FIB
prompts) with significant gains observed in the use of
these strategies across a 20-week treatment period [13,
14]. In addition, as has been found in prior studies con-
sidering this PILI approach, youth participants in both
treatment groups demonstrated gains in both the num-
ber of story-related utterances they produced during the
shared storytelling interaction and in their diversity of
vocabulary use [13]. Although the effort on the part of
parents is considerable, this replication of the efficacy of
PILI across multiple samples suggests that it can fill an
important void for older children and adolescents with
FXS, for whom there are limited evidence-based treat-
ment options.
It is interesting to note that parent, but not clinician,
ratings reflected improvements in communication—im-
provements that also emerged on the objective measures
derived from analyses of the parent-youth shared storytell-
ing interactions. It seems unlikely that the parent ratings
were merely reflecting placebo effects given their corres-
pondence with the objective measures. Instead, it may be
that clinicians, who had only limited interactions with the
youth with FXS and in a context (i.e., a clinic visit) un-
likely to yield high levels of youth engagement, may simply
not have had sufficient data regarding youth ability. In
contrast, the parents had more broad-based observations
available to them in the shared storytelling activities as
well as in a variety of daily activities and thus were able to
observe the real change that had occurred in their sons
and daughters. These data thus suggest that parents can
be accurate responders, and free of placebo effects, given
access to adequate data.
Interestingly, although comparable gains in both par-
ental use of the PILI-targeted intervention strategies and
youth gains were observed in both treatment groups,
parental use of the PILI strategies was correlated with
youth gains in both story-related utterances and diversity
of vocabulary used in the placebo group, but not in the
lovastatin group. It is possible, therefore, that lovastatin
may have modified or compensated for the relationship
between parent use of the PILI strategies and youth
gains that we were not able to directly measure in this
treatment design; however, this finding needs to repli-
cate with a new sample and is not, in and of itself, suffi-
cient reason to prescribe lovastatin for individuals with
FXS, especially because of the need for ongoing safety
monitoring with lovastatin.
Biomarkers of lovastatin-induced change
Finally, unlike some of the prior reports, MMP9, ERK1/
2, and S6K1 markers were comparable across the lova-
statin and placebo groups over the course of the study,
with neither group demonstrating significant changes in
any of the levels after accounting for pre-treatment
values. The elevated MMP9 levels observed in patients
with FXS enrolled in previous clinical trials were re-
duced in those treated with minocycline [72], which has
been shown to have a high potency in MMP-9 inhib-
ition, but they were not normalized in those treated with
sertraline [73]. FMRP binds and acts as a repressor of
translation of a number of mRNAs including those in-
volved in the ERK cascade signaling pathway [74]; thus,
the lack of this negative translational control is believed
to lead to upregulation of these pathways and
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consequently to the altered synaptogenesis observed in
FXS. Several studies have shown upregulation of ERK in
both mouse and human (reviewed in [75]), who, con-
trary to our observations, recently reported a reduction
of the ERK pathway signaling following a lovastatin
treatment. Specifically, they reported 1.6-fold increase in
basal ERK phosphorylation levels in blood platelets de-
rived from subjects with FXS, which was rescued by lov-
astatin treatment and correlated with clinical response.
This finding is not in line with the observations in this
study as we did not detect any difference or change in
phosphorylated ERK levels. The reason of this discrep-
ancy could be due to the use of blood platelets by Pel-
lerin and colleagues, whereas the present study utilized
plasma. We opted for plasma rather than platelets be-
cause the latter requires immediate processing, which is
not possible in many clinical trials, and there is a lack of
consensus in the field as to how platelets should be
processed in this context. Further, in addition to differ-
ent sample processing methods and potential differences
in expression levels among different tissues or cells, it is
well known that basal ERK phosphorylation levels are
very low in resting platelets giving a very low signal,
which if detected and quantified with a semiquantitative
approach, as is the Western blot used in the Pellerin’s
study, could affect the outcome. Thus, further large
studies are warranted to determine if the use of lova-
statin could lead to the normalization of ERK activity
and improve the FXS phenotype. Preclinical studies and
in human fibroblasts have suggested that inhibitors of
S6K1 should be considered for therapeutic intervention
in FXS [76–79]; however, this knowledge nor this target
biomarker has been successfully applied to human
clinical trials.
Limitations
There are a number of limitations to this study. As such,
the present results should be considered preliminary. An
important limitation is that a larger study was originally
planned, with a sample size of 104 (52 per group) and
projected dropout rate of 15%. That sample size would
have yielded 80% power to detect a standardized effect
size of 0.6 in a two-arm design for the primary outcome.
Difficulty in recruitment and more limited resources in
support of the project than expected led the authors to
conduct the present smaller-scale study. Although
speculative, our impression was that recruitment was
difficult because (a) some families were resistant to using
medication, especially one that is “experimental;” (b)
other families were unable to commit to the study be-
cause of the time involved in terms of study visits and
PILI training, especially in families in which both parents
held full-time employment; and (c) there were other
high-profile clinical trials recruiting simultaneously, and
thus, there was a competition for families at several uni-
versity sites across the country. In an attempt to remove
some of the barriers to participation, we plan to examine
different variants of PILI that involve added online mod-
ules, reduced synchronous coaching, and different inten-
sities and duration of training for parents. A second
limitation is that, although as discussed, there is evi-
dence that even adolescents with FXS can continue to
learn the language and so have the potential to benefit
from pharmacological intervention, that potential may
be greater in younger children; thus, testing of lovastatin
in a younger cohort would be useful in the future before
abandoning it as a treatment option. A third limitation
of the study is that the small number of females and
non-Caucasian participants in the study limits
generalizability. Finally, a longer study design is needed
to better understand if any long-term problems are asso-
ciated with the use of lovastatin in youth with FXS who
present with normal cholesterol levels. At the same time,
long-term post-treatment follow-up is needed to deter-
mine whether the benefits of PILI are maintained after
the intervention of the clinicians has ceased. In fact, one
of the arguments in favor of changing parent behavior is
that the parents can, hopefully, maintain the new behav-
ioral style and so their sons and daughters will continue
to benefit after the clinician-delivered training has
ceased. However, we have yet to document maintenance
of PILI benefits either for parent or child. Long-term
follow-up of PILI is now in progress.
Conclusions
The present study evaluated a 20-week controlled trial
of lovastatin in youth with FXS, paired with an open-
label treatment of PILI, to assess whether the benefits of
lovastatin combined with PILI would be greater than the
benefits of PILI alone. Significant improvements were
observed in all primary outcome measures, and in parent
report of severity of spoken language and social impair-
ments, in both treatment groups. Across the treatment
period, comparable amounts of change were observed in
both treatment groups. Although the hypothesis that the
benefits of lovastatin and PILI would be greater than the
benefits of PILI alone was not supported, data from the
present project provide additional support for the effi-
cacy of the use of PILI in youth with FXS.
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